Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Investor Presentation (November 2025)

37 slides from Day One Biopharmaceuticals's investor presentation, Nov 13, 2025

  1. Slide 1: Targeted therapies for people of all ages

    Slide 1: Targeted therapies for people of all ages

    Targeted therapies for people of all ages November 2025 Day One Biopharmaceuticals

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    2 Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, so

  3. Slide 3: Inspired by the urgent needs of children

    Slide 3: Inspired by the urgent needs of children

    3 Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life- threatening diseases

  4. Slide 4: Bringing life-changing medicines to patients sooner

    Slide 4: Bringing life-changing medicines to patients sooner

    Bringing life-changing medicines to patients sooner 4 • Commercial-stage biopharmaceutical company • Our goal is to develop and provide access to targeted new medicines to patients of all ages as rapidly as possible • Focused on advancing first- or best-in-class medicines for childhood and adult dis

  5. Slide 5: Day One's Future Potential Value creation

    Slide 5: Day One's Future Potential Value creation

    5 Day One’s Future Potential Value creation • Continued revenue growth from OJEMDA globally • Indication expansion in front-line pLGG with FIREFLY-2 • Generate clinical POC data in DAY301 program • Fund pipeline expansion • Maintaining a strong financial foundation through thoughtful capital allocat

  6. Slide 6: Product candidate pipeline

    Slide 6: Product candidate pipeline

    Product Candidate Therapeutic Area Phase 1 Dose Escalation Phase 1 Dose Optimization Phase 2 Phase 3/ Registrational Approved Recent & Anticipated Milestones Tovorafenib Type II RAF Inhibitor OJEMDA brand name in U.S.1 Ex-U.S. Rights: 3 BRAF-altered relapsed pLGG FDA accelerated approval April 2024

  7. Slide 7: Relapsed or refractory BRAF-altered pLGG: OJEMDA

    Slide 7: Relapsed or refractory BRAF-altered pLGG: OJEMDA

    Relapsed or refractory BRAF-altered pLGG OJEMDA 7 Nora Living with pLGG

  8. Slide 8: A serious and life-threatening disease

    Slide 8: A serious and life-threatening disease

    8 A serious and life-threatening disease *Incidence of BRAF alterations varies across pLGG subtypes. 1 Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009;24(11):1397-1408. doi:10.1177/0883073809342005. 2 Penman CL et al. Front Oncol. 2015;5:54. 3 Cohen AR., N Engl J Med. 2020;3

  9. Slide 9: Available in tablet and pediatric-friendly powder for oral suspension

    Slide 9: Available in tablet and pediatric-friendly powder for oral suspension

    9 Available in tablet formulation and pediatric-friendly powder for oral suspension Overview U.S. prescribing information for OJEMDA Indication OJEMDA is indicated for the treatment of pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRA

  10. Slide 10: Data from pivotal Phase 2 FIREFLY-1 trial

    Slide 10: Data from pivotal Phase 2 FIREFLY-1 trial

    10 Data from Pivotal Phase 2 FIREFLY-1 trial. • Meaningful tumor stabilization or shrinkage may be possible with OJEMDA, in the clinical trial: • 51% of children experienced tumor shrinkage by at least 25% • 82% of children saw their tumors shrink or remain stable Efficacy Safety • Generally well-to

  11. Slide 11: pLGG addressable opportunity

    Slide 11: pLGG addressable opportunity

    11 1 US Census. 2 CBTRUS, Qaddoumi et al 2009, Schreck et al 2019, ClearView Analysis. 3 Penman CL et al. Front Oncol. 2015;5:54. 4 Cohen AR., N Engl J Med. 2020;386(20):1922-1931. 5 Lassaletta A, et al. J Clin Oncol. 2017;35(25):2934-2941. 6 Faulkner C, et al. J Neuropathol Exp Neurol. 2015;74(9):8

  12. Slide 12: Delivering double-digit Q3 2025 growth across core metrics

    Slide 12: Delivering double-digit Q3 2025 growth across core metrics

    Delivering double-digit Q3 2025 growth across core metrics 12 1 Prescriptions are approximations based on data available as of September 30, 2025. Quarterly growth in net product revenue, prescriptions and new patient starts versus Q2 2025. 15% Growth in Net Product Revenue 18% $38.5M in Q3 2025 19%

  13. Slide 13: Commercial execution driving strong top-line growth

    Slide 13: Commercial execution driving strong top-line growth

    13 1 2024 net revenue included approximately $3.0M of revenue associated with Ex-U.S. sales which has been removed for the purposes of calculating compounded annual revenue growth rate. 2 Compounded annual growth represents the comparison of 2024 to Q3 2025 YTD U.S. net product revenue. Commercial e

  14. Slide 14: Accelerating uptake driving TRx growth

    Slide 14: Accelerating uptake driving TRx growth

    923 1,062 1,256 14 19% growth in new patient starts driven by 2-year follow up data3 Prescription Highlights • Gaining share in the 2L setting as prescriber confidence grows • High percentage of on-label patients staying on therapy month-to-month • ~90% of on-label patients receiving approval on fir

  15. Slide 15: Positive physician experience continues to build

    Slide 15: Positive physician experience continues to build

    Positive physician experience continues to build across treatment settings 15 1 Day One Biopharmaceuticals market research, self-reported data fielded September 2025 versus October 2024. 2L Adoption Increasing Strong Persistency 20 months median duration of treatment for EAP patients 75% of EAP pati

  16. Slide 16: Breadth and depth of prescribing by account

    Slide 16: Breadth and depth of prescribing by account

    16 1 Sequential growth refers to Q3 2025 versus Q2 2025. • >60% of prescribing accounts have treated multiple patients with OJEMDA • 28% sequential growth in number of accounts with 4 or more patients1 • >80% Priority 1 accounts have initiated 4 or more patients Launch Dec 2024 Sept 2025 1 Patient 2

  17. Slide 17: Focused execution driving continued adoption; raising 2025 guidance

    Slide 17: Focused execution driving continued adoption; raising 2025 guidance

    Focused execution and meaningful progress driving continued adoption and treatment durability through 2025 17 • On label patients only. Raising 2025 guidance to $145 - $150 million net product revenue OPTIMIZE PERSISTENCE Support physicians and patients to optimize their experience on OJEMDA includi

  18. Slide 18: Strengthening the OJEMDA story with FIREFLY-1 3-year data

    Slide 18: Strengthening the OJEMDA story with FIREFLY-1 3-year data

    We continue to strengthen the OJEMDA story through enhancing the target product profile and data generation 18 FIREFLY-1 3-Year Data Highlighting clinical stability following treatment with OJEMDA and opportunity for retreatment Potential to further expand physician confidence and adoption while rei

  19. Slide 19: OJEMDA IP summary and regulatory designations

    Slide 19: OJEMDA IP summary and regulatory designations

    19 OJEMDA IP summary and regulatory designations • Composition of matter patent of tovorafenib provides protection in the U.S. out to mid-2036 (with patent term extension)1 • Patent portfolio covers formulations, manufacturing methods, and uses of tovorafenib, with issued and pending applications po

  20. Slide 20: FIREFLY-2 front-line pLGG

    Slide 20: FIREFLY-2 front-line pLGG

    20 Pivotal Phase 3 trial of tovorafenib in front-line pLGG FIREFLY-2 Bradon Living with pLGG since age 11

  21. Slide 21: FIREFLY-2 trial design and endpoints

    Slide 21: FIREFLY-2 trial design and endpoints

    21 Trial design Endpoints • Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib vs SoC chemotherapy • Eligibility: Patients aged up to <25 years with LGG harboring a RAF alteration and requiring first-line systemic therapy • Tovorafenib available as tablets and pediatric-frie

  22. Slide 22: DAY301 PTK7-targeted ADC

    Slide 22: DAY301 PTK7-targeted ADC

    PTK7-targeted antibody-drug conjugate (ADC) 22 DAY301

  23. Slide 23: Substantial development and commercial potential for DAY301

    Slide 23: Substantial development and commercial potential for DAY301

    Substantial development and commercial potential for DAY301 Novel ADC active in preclinical models, designed to maximize therapeutic window 23 PTK7: clinically-validated ADC target Anti-tumor activity of anti-PTK7 ADC demonstrated in Phase 1b trial of cofetuzumab pelidotin1 DAY301: potential first-i

  24. Slide 24: PTK7: a clinically-validated ADC target

    Slide 24: PTK7: a clinically-validated ADC target

    24 Potential opportunity for a next-generation PTK7 ADC with improved therapeutic index • Clinical results for cofetuzumab pelidotin1 demonstrated proof of concept for PTK7-targeted ADCs • Cofetuzumab pelidotin activity seen in multiple tumor types: • Ovarian (Pt-resistant): ORR 27% (n=63) • TNBC: O

  25. Slide 25: DAY301: potential first-in-class asset

    Slide 25: DAY301: potential first-in-class asset

    25 DAY301 has been designed to maximize therapeutic index and overcome limitations of prior programs • Tumor regression at tolerable doses seen in multiple preclinical models • Higher HNSTD in cyno toxicology studies; payload with known safety profile • High cell permeability / bystander effect; low

  26. Slide 26: Improved tumor regression for DAY301 vs. benchmarks in preclinical models

    Slide 26: Improved tumor regression for DAY301 vs. benchmarks in preclinical models

    26 26 Improved tumor regression activity demonstrated for DAY301 vs. benchmarks in multiple preclinical models DAY301: First-in-class potential PDX LD1-200615 HNSCC H-score 120 Vehicle Control antibody + DAY301 payload Control antibody + auristatin payload Cofetuzumab pelidotin, 5 mg/kg DAY301, 10 m

  27. Slide 27: PTK7 expression and patient populations by indication

    Slide 27: PTK7 expression and patient populations by indication

    27 Indication PTK7 Expression (>1+) U.S. Patient Population Cases/Deaths ORR at Relapse Median OS at Relapse Endometrial 100%2 67,880/13,2503 39%7 9 months7 Esophageal SCC 76%1 22,370/16,1303 5%4 3 months4 Gastric 35%2 26,890/10,8803 12%14 6-14 months15 Head & Neck SCC 75%1 54,540/11,5803 32%5 7.8 m

  28. Slide 28: DAY301 Phase 1 clinical development plan

    Slide 28: DAY301 Phase 1 clinical development plan

    28 Phase 1a: Monotherapy Dose Escalation FDA-cleared starting dose DL5 RD1 RD2 Identify two recommended dose levels for further evaluation, based on safety and anti-tumor activity • BOIN design for efficiency of dose escalation • Backfill active dose levels to generate additional safety data • Enrol

  29. Slide 29: Emi-Le B7-H4-targeted ADC

    Slide 29: Emi-Le B7-H4-targeted ADC

    B7-H4-targeted antibody-drug conjugate (ADC) 29 Emi-Le

  30. Slide 30: Emi-Le: opportunity in adenoid cystic carcinoma

    Slide 30: Emi-Le: opportunity in adenoid cystic carcinoma

    30 Emi-Le represents a transformational opportunity to address the unmet need for patients with adenoid cystic carcinoma (ACC) • ACC is a rare cancer, with an annual US incidence of ~1,300 patients2 • Recurrent/metastatic ACC often presents with aggressive features; no approved therapeutic options e

  31. Slide 31: Summary

    Slide 31: Summary

    31 Summary

  32. Slide 32: Third quarter 2025 financial results

    Slide 32: Third quarter 2025 financial results

    32 Third quarter 2025 financial results All financial information as of 9/30/25 is unaudited. 1 Includes stock-based compensation expense of $3.0 million and $10.8 million for the three and nine months ended 9/30/25, and $3.8 million and $13.2 million for the three and nine months ended 9/30/24. 2 I

  33. Slide 33: Well positioned for sustainable growth and long-term success

    Slide 33: Well positioned for sustainable growth and long-term success

    33 Day One is well positioned for sustainable growth and long-term success Drive OJEMDA revenue growth Execute on clinical development pipeline for FIREFLY-2 and DAY301 Leverage our development and commercialization expertise to further expand our multiple asset portfolio Maintain strong capital pos

  34. Slide 34: Appendix

    Slide 34: Appendix

    Appendix 34

  35. Slide 35: Tovorafenib is an oral, selective, CNS-penetrant type II RAF inhibitor

    Slide 35: Tovorafenib is an oral, selective, CNS-penetrant type II RAF inhibitor

    35 Tovorafenib is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase • Activity in tumors driven by both RAF fusions and BRAF V600E mutations • Tablet and pediatric-friendly liquid suspension • Once weekly dosi

  36. Slide 36: 51% overall response rate in evaluable patients

    Slide 36: 51% overall response rate in evaluable patients

    36 51% Overall response rate (RAPNO-LGG) in 76 evaluable patients Response (IRC) RAPNO-LGG n n (%) 95% CI ORR, n (%) BRAF fusion or rearrangement BRAF V600 mutation Prior MAPKi use MAPKi-naïve Median DOR, months Median TTR, months Range 76 64 12 45 31 39 39 39 (51) 33 (52) 6 (50) 22 (49) 17 (55) 13.

  37. Slide 37: Warnings and Precautions; safety data

    Slide 37: Warnings and Precautions; safety data

    37 Warnings and Precautions • Hemorrhage • Skin toxicity, including photosensitivity • Hepatotoxicity • Effect on growth • Embryo-fetal toxicity • Use in NF1- associated tumors No boxed warnings or contraindications TEAEs (≥ 30% of patients [n=137]) Preferred Term, n (%) Any Grade Grade ≥3 Any AE 13

Source: SEC EDGAR · 8-K filed Nov 13, 2025

More decks from Day One Biopharmaceuticals Inc